Pricing

In establishing the value of new medicines, old-way theory is yielding to real-world practice - but there are risks in being 'of the moment'.

Diagnostics can bost the efficacy of drug treatments, but delivering the promise depends on a predictible pathway to reimbursement.

Do drug co-pay cards lead to skyrocketing healthcare inflation or provide patients access to valuable medicines?

The strict regulatory divide between market authorization and price reimbursement iscrumbling in the US. Is industry prepared to adapt or challenge?

The Deficit Reduction Act was designed to save the government money on Medicaid. But it also has the potential to change the very way pharma companies conduct business-if they can just figure it out.